Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression

Progestins has been used widely for endometrial cancer (EC) patients. However, long term use of high dose progestin often lead to progestin resistance. Our previous studies have demonstrated that metformin reversed progestin resistance through the downregulation of the expression of glyoxalase I (GL...

Full description

Bibliographic Details
Main Authors: Yanyu Jiang, Xiong Chen, Youheng Wei, Youji Feng, Wenxin Zheng, Zhenbo Zhang
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332219304056
id doaj-5c68809e36944f14b7f4ed82591fa137
record_format Article
spelling doaj-5c68809e36944f14b7f4ed82591fa1372021-05-20T07:37:37ZengElsevierBiomedicine & Pharmacotherapy0753-33222019-05-01113Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expressionYanyu Jiang0Xiong Chen1Youheng Wei2Youji Feng3Wenxin Zheng4Zhenbo Zhang5Reproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, ChinaDepartment of Obstetrics and Gynecology, Shanghai First People’s Hospital, Baoshan Branch, Shanghai, 201900, ChinaInstitute of Bioscience and Biotechnology, Yangzhou University, Yangzhou, ChinaReproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, ChinaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USAReproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China; Department of Obstetrics and Gynecology, Shanghai First People’s Hospital, Baoshan Branch, Shanghai, 201900, China; Corresponding author at: Reproductive Medicine Center, Shanghai General Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai 200080, China.Progestins has been used widely for endometrial cancer (EC) patients. However, long term use of high dose progestin often lead to progestin resistance. Our previous studies have demonstrated that metformin reversed progestin resistance through the downregulation of the expression of glyoxalase I (GLOI) in type I endometrial cancer. Recent studies have demonstrated the role of Ten-eleven translocation 1 (TET1) in endometrial cancer, but the physiological role of TET1 in GLOI-mediated progestin resistance has been poorly addressed. Immunohistochemistry was used to detect the expression of TET1, GLOI and 5hmC in various endometrium. Western blot was carried out to analyses TET1 and GLOI expression with different treatment. Cell counting kit-8 was used to evaluate cell proliferation after various treatment. Dot blot assay and HMeDIP assay were performed to detect global hydroxmethylation levels and hydroxymethylation levels in GLOI gene respectively. In current study, we found that metformin effectively sensitized progestin in endometrial cancer cell lines through the down regulation of the expression of TET1 and GLOI. Interestingly, the exogenous increase of TET1 expression enhanced total 5hmC level and hydroxymethylation modification in glyoxalase I promoter region. This effect was abated by metformin treatment. Moreover, the expression profile of TET1 and glyoxalase I in various endometrial tissue parallelized with 5hmC level. Therefore, this finding suggests that metformin sensitized progestin in endometrial cancer through the TET1-5hmC-GLOI signaling pathway.http://www.sciencedirect.com/science/article/pii/S0753332219304056Endometrial cancerMetforminTET1GLOI5hmC
collection DOAJ
language English
format Article
sources DOAJ
author Yanyu Jiang
Xiong Chen
Youheng Wei
Youji Feng
Wenxin Zheng
Zhenbo Zhang
spellingShingle Yanyu Jiang
Xiong Chen
Youheng Wei
Youji Feng
Wenxin Zheng
Zhenbo Zhang
Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression
Biomedicine & Pharmacotherapy
Endometrial cancer
Metformin
TET1
GLOI
5hmC
author_facet Yanyu Jiang
Xiong Chen
Youheng Wei
Youji Feng
Wenxin Zheng
Zhenbo Zhang
author_sort Yanyu Jiang
title Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression
title_short Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression
title_full Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression
title_fullStr Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression
title_full_unstemmed Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression
title_sort metformin sensitizes endometrial cancer cells to progestin by targeting tet1 to downregulate glyoxalase i expression
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2019-05-01
description Progestins has been used widely for endometrial cancer (EC) patients. However, long term use of high dose progestin often lead to progestin resistance. Our previous studies have demonstrated that metformin reversed progestin resistance through the downregulation of the expression of glyoxalase I (GLOI) in type I endometrial cancer. Recent studies have demonstrated the role of Ten-eleven translocation 1 (TET1) in endometrial cancer, but the physiological role of TET1 in GLOI-mediated progestin resistance has been poorly addressed. Immunohistochemistry was used to detect the expression of TET1, GLOI and 5hmC in various endometrium. Western blot was carried out to analyses TET1 and GLOI expression with different treatment. Cell counting kit-8 was used to evaluate cell proliferation after various treatment. Dot blot assay and HMeDIP assay were performed to detect global hydroxmethylation levels and hydroxymethylation levels in GLOI gene respectively. In current study, we found that metformin effectively sensitized progestin in endometrial cancer cell lines through the down regulation of the expression of TET1 and GLOI. Interestingly, the exogenous increase of TET1 expression enhanced total 5hmC level and hydroxymethylation modification in glyoxalase I promoter region. This effect was abated by metformin treatment. Moreover, the expression profile of TET1 and glyoxalase I in various endometrial tissue parallelized with 5hmC level. Therefore, this finding suggests that metformin sensitized progestin in endometrial cancer through the TET1-5hmC-GLOI signaling pathway.
topic Endometrial cancer
Metformin
TET1
GLOI
5hmC
url http://www.sciencedirect.com/science/article/pii/S0753332219304056
work_keys_str_mv AT yanyujiang metforminsensitizesendometrialcancercellstoprogestinbytargetingtet1todownregulateglyoxalaseiexpression
AT xiongchen metforminsensitizesendometrialcancercellstoprogestinbytargetingtet1todownregulateglyoxalaseiexpression
AT youhengwei metforminsensitizesendometrialcancercellstoprogestinbytargetingtet1todownregulateglyoxalaseiexpression
AT youjifeng metforminsensitizesendometrialcancercellstoprogestinbytargetingtet1todownregulateglyoxalaseiexpression
AT wenxinzheng metforminsensitizesendometrialcancercellstoprogestinbytargetingtet1todownregulateglyoxalaseiexpression
AT zhenbozhang metforminsensitizesendometrialcancercellstoprogestinbytargetingtet1todownregulateglyoxalaseiexpression
_version_ 1721435328120619008